Former Food and Drug Administration Commissioner Scott Gottlieb says opening up patient access to therapies through the Medicare market can play a key role to support a number of patients by implementing a payment-over-time model for high-cost therapies.
Gottlieb made the comments during a recent interview with the American Journal of Managed Care.
” … In the Senate bill that was introduced there is a proposal to allow Medicaid plans in particular to try to amortize the cost of delivering curative gene therapy, particularly for things like inherited disorders,” Gottlieb said. “I think this is going to be important because these treatments — if you’re targeting even a multi-million-dollar gene therapy to a very rare, let’s say a pediatric inherited disease that’s extremely rare — that’s largely an insurable risk in the private market.”
To watch the interview on AJMC’s website, click here.